Deflazacort (Emflaza) is a drug used in the treatment of Duchenne muscular dystrophy (DMD). It’s generally given to patients five years and older and is a type of corticosteroid precursor which acts as an immunosuppressant and anti-inflammatory medication.
Conducted in 1995, clinical trials of the drug found that taking deflazacort over a prolonged period of time (52 weeks) resulted in improved muscle strength and in some cases basic functions also improved, like the length of time it took to stand, climb stairs or walk a certain distance.
Side effects of the drug included headaches, facial puffiness, increased appetite and weight gain (although less weight was gained by those on the trial compared to boys taking prednisone), cough and colds, increased urination during the day, and excessive hair growth. Find out more about deflazacort here.
Muscular Dystrophy News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.